Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What are the purposes of using epinephrine in conjunction with local anesthetics?

All of the options. ***All of the options*** - Epinephrine is a **vasoconstrictor** that produces all three of the listed benefits when combined with local anesthetics. - The **vasoconstrictive effect** reduces blood flow at the injection site, which simultaneously achieves multiple therapeutic purposes. - All three mechanisms work together through a single pharmacological action: **local vasoconstriction**. **1. Prolongs the duration of anesthesia:** - Vasoconstriction reduces blood flow to the area, delaying the washout of the local anesthetic from the nerve site. - This maintains a higher local concentration of anesthetic for a longer period, extending the duration of nerve block. - Duration can be increased by 50-100% depending on the site and anesthetic used. **2. Decreases systemic absorption:** - By constricting local blood vessels, epinephrine slows the rate at which the local anesthetic enters the systemic circulation. - This reduces peak plasma concentrations, **lowering the risk of systemic toxicity** (CNS and cardiac effects). - Allows use of higher total doses of local anesthetic when needed. **3. Reduces bleeding:** - The vasoconstrictive effect directly narrows small blood vessels in the surgical field. - This **reduces capillary bleeding**, improving surgical visibility and decreasing blood loss during procedures. - Particularly useful in highly vascular areas like the oral cavity and scalp.

Q: A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

10 mg. ***10 mg*** - The **therapeutic index (TI)** is calculated as **LD50 / ED50**. - Given a TI of 5 and an ED50 of 2 mg, the LD50 = TI × ED50 = 5 × 2 mg = **10 mg**. - This is the correct application of the therapeutic index formula. *15 mg* - This value would imply a therapeutic index of 7.5 (15 mg / 2 mg), which is incorrect based on the given information. - Does not align with the definition and calculation of the therapeutic index. *8 mg* - This value would result in a therapeutic index of 4 (8 mg / 2 mg), not the given TI of 5. - Represents an incorrect application of the therapeutic index formula. *12 mg* - This value would yield a therapeutic index of 6 (12 mg / 2 mg), differing from the provided TI of 5. - Does not correctly reflect the relationship between ED50, LD50, and the therapeutic index.

Q: What is the primary concern regarding the dosing of statins in patients with hepatic impairment?

Increased risk of toxicity due to reduced clearance. Increased risk of toxicity due to reduced clearance - Hepatic impairment significantly reduces the liver's ability to metabolize and clear statins from the body - This reduced clearance results in higher systemic exposure to the drug, increasing the risk of dose-dependent adverse effects such as myopathy and rhabdomyolysis [1] - The primary clinical concern is the increased toxicity risk, which necessitates careful dose adjustment and monitoring Potential for reduced efficacy due to altered metabolism - While metabolism may be altered, the primary concern is increased drug levels rather than reduced efficacy [2] - Most statins are metabolized to active or inactive metabolites, and hepatic impairment typically increases rather than decreases drug exposure [2] - Reduced efficacy is uncommon unless severe hepatic dysfunction prevents conversion of prodrug statins Need for mandatory dose reduction in all cases regardless of severity - Dose adjustment is not automatically required in all cases of hepatic impairment - Management depends on the severity of hepatic dysfunction (Child-Pugh class) and the specific statin used - Some statins (e.g., rosuvastatin, pravastatin) undergo minimal hepatic metabolism and may be safer options - The concern is toxicity risk, not blanket dose reduction Altered bioavailability due to first-pass metabolism - While first-pass metabolism can be altered in hepatic impairment, this typically results in increased bioavailability for highly extracted drugs [2] - Increased bioavailability would contribute to higher systemic exposure and toxicity, not a separate primary concern - The core issue remains overall drug accumulation and toxicity risk [1]

Q: A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

Lower therapeutic index, increased risk of toxicity. ***Lower therapeutic index, increased risk of toxicity*** - When the **therapeutic and toxic dose-response curves are closely positioned**, there is a narrow margin between the dose that produces therapeutic effects and the dose that causes toxicity - This narrow separation indicates a **low therapeutic index (TI = TD50/ED50)**, where TD50 (toxic dose) and ED50 (effective dose) are close in value - Clinically, this means **increased risk of toxicity** as small dose increases or patient variability can easily shift from therapeutic to toxic range - Examples include drugs like **digoxin, warfarin, and aminoglycosides** which require careful monitoring *Higher therapeutic index, increased safety* - This would be true if the toxic dose-response curve was **far separated** from the therapeutic curve on the dose axis - Close positioning of curves indicates **low, not high** therapeutic index - Higher therapeutic index drugs have a wide safety margin (e.g., penicillins, most NSAIDs) *Lower therapeutic index, unchanged efficacy* - While **lower therapeutic index** is correct, "unchanged efficacy" is not a relevant inference from curve positioning - **Efficacy** refers to the maximal effect (Emax), represented by the plateau height of the dose-response curve, not its position on the dose axis - Therapeutic index and efficacy are independent parameters *Higher therapeutic index, unchanged potency* - Close positioning of therapeutic and toxic curves indicates **lower, not higher** therapeutic index - **Potency** (dose required for effect, reflected by ED50 position) is independent of therapeutic index - A drug can be highly potent but have a low therapeutic index if toxic effects occur at doses close to therapeutic doses

Q: What is the benefit of combining levodopa with carbidopa in the treatment of Parkinson's disease?

Reduces peripheral side effects of levodopa. ***Reduces peripheral side effects of levodopa*** - Carbidopa is a **dopa decarboxylase inhibitor** that does not cross the blood-brain barrier. It inhibits the peripheral conversion of levodopa to dopamine, thereby reducing peripheral side effects like **nausea**, **vomiting**, and **cardiac arrhythmias**. - By reducing peripheral metabolism, more levodopa is available to cross the **blood-brain barrier** and be converted to dopamine in the brain, improving therapeutic efficacy. *Enhances CNS penetration of levodopa* - Carbidopa itself **does not cross the blood-brain barrier**, so it cannot directly enhance the central nervous system (CNS) penetration of levodopa. - Its action is primarily in the **periphery**, preventing levodopa's premature conversion to dopamine before it reaches the brain. *Prolongs the half-life of levodopa* - While carbidopa increases the amount of levodopa available to the brain, it does not significantly **prolong the plasma half-life** of levodopa itself. - The primary effect is to **reduce peripheral metabolism**, allowing a greater proportion of the administered dose to reach the CNS. *Increases dopamine receptor sensitivity* - Carbidopa's mechanism of action involves **enzyme inhibition** (dopa decarboxylase) and does not directly affect the sensitivity of **dopamine receptors** in the brain. - Levodopa is converted to dopamine, which then acts on these receptors, but carbidopa does not modulate their sensitivity.

Q: A 30-year-old woman requires drug administration with 100% bioavailability. Which of the following routes will ensure this requirement?

Intravenous. ***Intravenous*** - **Intravenous (IV)** administration delivers the drug directly into the **bloodstream**, bypassing all absorption barriers and **first-pass metabolism**, ensuring **100% bioavailability by definition**. - This is the **only route** (along with intra-arterial) that guarantees complete bioavailability since the entire drug dose reaches systemic circulation. - Provides immediate and precise control over drug plasma levels. *Oral* - **Oral administration** is subject to significant **first-pass metabolism** in the liver and gastrointestinal degradation, leading to bioavailability **less than 100%**. - The drug must pass through the GI tract and undergo hepatic metabolism before reaching systemic circulation, which reduces the amount of active drug available. *Subcutaneous* - **Subcutaneous (SC)** administration requires absorption from the fatty tissue under the skin, which can be **slow and incomplete**, resulting in bioavailability **less than 100%**. - Factors like blood flow to the injection site, drug solubility, and molecular size significantly affect absorption. *Intramuscular* - **Intramuscular (IM)** administration generally provides good bioavailability (often 80-90%), but it is **rarely 100%** due to the need for absorption from muscle tissue into the bloodstream. - The rate and extent of absorption depend on muscle blood flow, injection site, and drug formulation.

Q: A pharmacokinetic study of a new drug reveals that it follows first-order kinetics. What does this imply about the drug's elimination?

A constant fraction of drug is eliminated per unit time. ***A constant fraction of drug is eliminated per unit time*** - In **first-order kinetics**, the rate of drug elimination is directly proportional to the drug concentration [1]. - This means that a **constant percentage** or **fraction** of the drug is removed from the body per unit of time, regardless of the absolute amount present [2]. *A constant amount of drug is eliminated per unit time* - This describes **zero-order kinetics**, where the elimination pathways are saturated, and a fixed amount of drug is eliminated per unit of time [2]. - This is typical for drugs like **ethanol** at higher concentrations or **phenytoin** at therapeutic doses [1]. *The drug has a variable half-life* - Drugs following **first-order kinetics** have a **constant half-life**, meaning the time it takes for half of the drug to be eliminated from the body remains the same regardless of the initial concentration. - A variable half-life is more characteristic of **zero-order kinetics**, as the time to eliminate half the drug would depend on the current drug concentration. *The drug accumulates in the body over time* - While accumulation can occur with any drug if the dosing interval is too short or the dose is too high relative to elimination, **first-order kinetics** itself does not inherently imply accumulation if dosed appropriately. - Accumulation is more problematic with **zero-order kinetics** because the elimination rate does not increase with concentration, leading to a higher risk of toxicity.

Question 1

Which of the following statements is true regarding zero-order kinetics?

Accepted Answer

Follows a constant rate of elimination regardless of concentration.

Answer

Commonly seen in therapeutic doses of most drugs.

Answer

Rate of elimination depends on drug concentration.

Answer

Occurs only at subtherapeutic doses of drugs.

Question 2

A patient with hypercholesterolemia has a mutation in the LDL receptor gene. Evaluate the potential effect of statin therapy in this patient.

Accepted Answer

Increased LDL receptor expression, reduced cholesterol synthesis

Answer

Decreased LDL receptor expression, increased cholesterol synthesis

Answer

Increased LDL receptor expression, increased cholesterol synthesis

Answer

Decreased LDL receptor expression, reduced cholesterol synthesis

Question 3

What are the purposes of using epinephrine in conjunction with local anesthetics?

Accepted Answer

All of the options

Answer

To prolong the duration of anesthesia

Answer

To decrease systemic absorption

Answer

To reduce bleeding

Question 4

A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

Accepted Answer

10 mg

Answer

15 mg

Answer

8 mg

Answer

12 mg

Question 5

What is the primary concern regarding the dosing of statins in patients with hepatic impairment?

Accepted Answer

Increased risk of toxicity due to reduced clearance

Answer

Potential for reduced efficacy due to altered metabolism

Answer

Altered bioavailability due to first-pass metabolism

Answer

Need for mandatory dose reduction in all cases regardless of severity

Question 6

A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

Accepted Answer

Lower therapeutic index, increased risk of toxicity

Answer

Higher therapeutic index, increased safety

Answer

Lower therapeutic index, unchanged efficacy

Answer

Higher therapeutic index, unchanged potency

Question 7

When comparing oral and intravenous routes of administration, which statement best describes the difference in bioavailability?

Accepted Answer

Oral has lower bioavailability due to first-pass metabolism.

Answer

Oral has lower bioavailability due to prolonged absorption.

Answer

Intravenous has higher bioavailability due to rapid distribution.

Answer

Intravenous has higher bioavailability due to increased absorption.

Question 8

What is the benefit of combining levodopa with carbidopa in the treatment of Parkinson's disease?

Accepted Answer

Reduces peripheral side effects of levodopa

Answer

Enhances CNS penetration of levodopa

Answer

Prolongs the half-life of levodopa

Answer

Increases dopamine receptor sensitivity

Question 9

A 30-year-old woman requires drug administration with 100% bioavailability. Which of the following routes will ensure this requirement?

Accepted Answer

Intravenous

Answer

Oral

Answer

Subcutaneous

Answer

Intramuscular

Question 10

A pharmacokinetic study of a new drug reveals that it follows first-order kinetics. What does this imply about the drug's elimination?

Accepted Answer

A constant fraction of drug is eliminated per unit time

Answer

A constant amount of drug is eliminated per unit time

Answer

The drug has a variable half-life

Answer

The drug accumulates in the body over time

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?